Antidiarrheals Global Market Report 2024

“Antidiarrheals Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on antidiarrheals market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for antidiarrheals? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The antidiarrheals market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:

• 1) By Drug Class: Mucosal Protectants; Motility Modifying Drugs
• 2) By Application: Adults; Childrens
• 3) By Type: OTC drugs; Prescription Drugs
• Companies Mentioned: GlaxoSmithKline plc; Actelion Pharmaceuticals Ltd (a subsidiary of Johnson & Johnson); Perrigo Company plc; Lupin Limited; Glenmark Pharmaceuticals Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Antidiarrheal drugs are medications designed to alleviate the symptoms of diarrhea, particularly the frequent passage of watery and loose stools. These drugs can be categorized into three primary groups based on their chemical or functional properties including adsorbents, antimotility agents, and bacterial replacements (probiotics).

The two major classes of antidiarrheal drugs are mucosal protectants and motility-modifying drugs. Mucosal protectants are drugs that serve to protect the stomach's mucosal lining from the corrosive effects of gastric acid and are commonly used in the treatment of peptic ulcers. These agents are available in various forms, including over-the-counter (OTC) medications and prescription drugs, suitable for both adults and children.

The antidiarrheal drugs market research report is one of a series of new reports from The Business Research Company that provides antidiarrheal drugs market statistics, including antidiarrheal drugs industry global market size, regional shares, competitors with antidiarrheal drugs market share, detailed antidiarrheal drugs market segments, market trends and opportunities, and any further data you may need to thrive in the antidiarrheal drugs industry. This antidiarrheal drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The antidiarrhoeals market size has grown steadily in recent years. It will grow from $3.76 billion in 2023 to $3.89 billion in 2024 at a compound annual growth rate (CAGR) of 3.3%. The growth observed during the historical period can be attributed to several key factors, including the prevalence of diseases, global health initiatives, an aging population, pharmaceutical innovation, and increased patient awareness.

The antidiarrhoeals market size is expected to see steady growth in the next few years. It will grow to $4.41 billion in 2028 at a compound annual growth rate (CAGR) of 3.2%. The anticipated growth in the forecast period can be attributed to various factors, including the expansion of emerging markets, environmental considerations, global health challenges, epidemiology, and the burden of disease. Additionally, significant trends in this forecast period encompass the rise of digital health and telemedicine, a shift toward patient-centric care, the popularity of self-care and over-the-counter (OTC) products, the advancement of personalized medicine, and the progress in biotechnology.

The increasing number of diarrhea cases plays a significant role in driving the growth of the antidiarrheal drug market. As reported by UNICEF, diarrhea stands as the second leading cause of death among children under 5 years of age, responsible for claiming the lives of 760,000 children annually. The growing prevalence of diarrhea underscores the heightened demand for antidiarrheal drugs in the market.

The growing prevalence of gastroparesis is anticipated to drive the expansion of the antidiarrheal market. Gastroparesis is a medical condition characterized by the slowing down or delay of food movement from the stomach to the small intestine. This condition can be triggered by various factors, including hypothyroidism, autoimmune diseases, injury to the vagus nerve, and viral stomach infections. Antidiarrheal medications are used to manage gastroparesis and alleviate symptoms such as cramps, bloating, and pressure. For example, in 2021, a research study published by Practice Update, a Netherlands-based online publisher of research articles, reported that the overall prevalence rate of gastroparesis in the US was 267.7 cases per 100,000 individuals, with a prevalence rate of definite gastroparesis at 21.5 cases per 100,000 persons. This increasing prevalence of gastroparesis is expected to be a driving factor in the growth of the antidiarrheal market.

The increased utilization of biologic medicines serves as a constraint for the antidiarrheal market. Biologics are medications derived from living organisms, including humans, animals, or other microorganisms, utilizing biotechnology. They are composed of proteins, sugars, nucleic acids, or a combination of these substances. Biologics have gained preference over traditional chemical drugs due to their ability to target previously inaccessible areas using small-molecule therapies. This shift towards biologics is limiting the growth of the antidiarrheal drugs market. For instance, in the treatment of conditions like Crohn's Disease, antidiarrheal medications were previously employed. However, with the emergence of biologics, the demand for antidiarrheal drugs has diminished as they are being used to address the underlying disease more effectively.

Prominent companies operating in the antidiarrheal drug market are actively engaging in mergers and acquisitions with other players in the industry as a strategic approach to expand their market reach and increase their market share. Such mergers and acquisitions allow companies to enhance their market presence, diversify their product portfolios, and gain access to new technologies and capabilities. For example, GlaxoSmithKline's agreement to acquire Novartis AG's 36.5% stake in the consumer healthcare business for $13 billion is a notable move aimed at expanding their presence in the market. This demonstrates a common industry strategy to strengthen and grow their positions through strategic alliances and business combinations.

Major companies in the antidiarrheal drug market are actively involved in product innovation to enhance their profitability. One such innovation is the development of Nitazoxanide Tablets, which are prescribed for the treatment of diarrhea caused by specific parasitic infections in the gastrointestinal tract. For example, in March 2021, Lupin Limited, a US-based pharmaceutical company, introduced the authorized generic version of Alinia (nitazoxanide) Tablets. Nitazoxanide Tablets are indicated for managing diarrhea resulting from Giardia lamblia or Cryptosporidium parvum infections in patients aged 12 years and above. This type of innovation is aimed at addressing specific healthcare needs and expanding the product portfolio, thus contributing to increased profitability in the antidiarrheal drug market.

In September 2021, AzurRx BioPharma, a US-based biotechnology company, completed the acquisition of First Wave Bio, Inc. for a total of $229 million. This strategic acquisition served to diversify AzurRx's portfolio by adding a range of new treatments for inflammatory bowel disease, all of which are based on the use of niclosamide. First Wave Bio, Inc. is a biotech company also based in the United States.

Major companies operating in the antidiarrhoeals market include GlaxoSmithKline PLC, Actelion Pharmaceuticals Ltd (a subsidiary of Johnson & Johnson), Perrigo Company PLC, Lupin Limited, Glenmark Pharmaceuticals Limited, Merck & Co. Inc., Pfizer Inc., The Procter & Gamble Company, Sanofi-aventis U.S. LLC, Bayer AG, Johnson & Johnson, Novartis International AG, The Kroger Co., Harmon Stores Inc., Great Lakes Wholesale Marketing and Sales Inc., Geri-Care Pharmaceuticals Corp., Fred's Inc., Dolgen Corporation, CVS Pharmacy Inc., American Sales Company, Cardinal Health Inc., Bedrock LLC, Greenbrier International Inc., Good Neighbor Pharmacy, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Mylan N.V., Dr. Reddy's Laboratories Ltd., Cadila Healthcare Ltd., Torrent Pharmaceuticals Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Alkem Laboratories Ltd., Zydus Cadila Healthcare Ltd.

North America was the largest region in the antidiarrhoeals market in 2023. The regions covered in the antidiarrhoeals market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antidiarrhoeals market report are: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The antidiarrheal drugs market consists of sales loperamide hydrochloride, Bismuth subsalicylate, Pepto Bismol and Imodium. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.